A retrospective study assessing the cumulative incidence of relapse (CIR), overall survival (OS), and progression-free survival (PFS) and the incidence of acute and chronic graft-versus-host disease (GVHD) of patients with high-risk AML or MDS
Latest Information Update: 10 Nov 2021
Price :
$35 *
At a glance
- Drugs Azacitidine (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 10 Nov 2021 New trial record
- 01 Oct 2021 Results published in the Transplantation and Cellular Therapy